NCT00506831View on ClinicalTrials.gov

Imatinib in Systemic Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Scleroderma, Systemic
Interventions
DRUG

Imatinib mesylate

100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00506831 - Imatinib in Systemic Sclerosis | Biotech Hunter | Biotech Hunter